Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea
· Delayed Price · Currency is KRW 15,410
+160 (1.05%)
At close: Mar 9, 2026
Hyundai Bioscience Revenue
Hyundai Bioscience had revenue of 553.06M KRW in the quarter ending September 30, 2025, with 20.56% growth. This brings the company's revenue in the last twelve months to 1.96B, down -87.61% year-over-year. In the year 2024, Hyundai Bioscience had annual revenue of 15.05B with 58.73% growth.
Revenue (ttm)
1.96B
Revenue Growth
-87.61%
P/S Ratio
747.11
Revenue / Employee
28.41M
Employees
69
Market Cap
1,464.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15.05B | 5.57B | 58.73% |
| Dec 31, 2023 | 9.48B | 1.63B | 20.76% |
| Dec 31, 2022 | 7.85B | -1.39B | -15.04% |
| Dec 31, 2021 | 9.24B | -3.27B | -26.14% |
| Dec 31, 2020 | 12.51B | -17.57B | -58.41% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,556.97B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| Sam Chun Dang Pharm. | 220.74B |
| Oscotec | 23.23B |
| Daewoong Pharmaceutical | 1,541.65B |
| Chabiotech | 1,197.69B |
| GC Biopharma | 1,934.38B |